25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

524404 (Marksans Pharma Limited) Stock Analysis
Buy, Hold or Sell?

Let's analyze Marksans Pharma Limited together

I guess you are interested in Marksans Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Marksans Pharma Limited’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Marksans Pharma Limited’s Price Targets

I'm going to help you getting a better view of Marksans Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Marksans Pharma Limited

I send you an email if I find something interesting about Marksans Pharma Limited.

1. Quick Overview

1.1. Quick analysis of Marksans Pharma Limited (30 sec.)










1.2. What can you expect buying and holding a share of Marksans Pharma Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.03
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR54.44
Expected worth in 1 year
INR118.15
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR66.11
Return On Investment
37.2%

For what price can you sell your share?

Current Price per Share
INR177.85
Expected price per share
INR157.97 - INR248.62
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Marksans Pharma Limited (5 min.)




Live pricePrice per Share (EOD)
INR177.85
Intrinsic Value Per Share
INR-27.48 - INR23.66
Total Value Per Share
INR26.95 - INR78.10

2.2. Growth of Marksans Pharma Limited (5 min.)




Is Marksans Pharma Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$278.7m???

How much money is Marksans Pharma Limited making?

Current yearPrevious yearGrowGrow %
Making money$43m???
Net Profit Margin14.5%?--

How much money comes from the company's main activities?

2.3. Financial Health of Marksans Pharma Limited (5 min.)




2.4. Comparing to competitors in the Drug Manufacturers - Major industry (5 min.)




  Industry Rankings (Drug Manufacturers - Major)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Marksans Pharma Limited?

Welcome investor! Marksans Pharma Limited's management wants to use your money to grow the business. In return you get a share of Marksans Pharma Limited.

First you should know what it really means to hold a share of Marksans Pharma Limited. And how you can make/lose money.

Speculation

The Price per Share of Marksans Pharma Limited is INR177.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Marksans Pharma Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Marksans Pharma Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR54.44. Based on the TTM, the Book Value Change Per Share is INR15.93 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.60 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Marksans Pharma Limited.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.090.1%0.090.1%0.080.0%0.070.0%0.040.0%
Usd Book Value Change Per Share0.180.1%0.180.1%0.140.1%0.110.1%0.060.0%
Usd Dividend Per Share0.010.0%0.010.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.190.1%0.190.1%0.150.1%0.110.1%0.060.0%
Usd Price Per Share2.51-2.51-1.65-1.10-0.69-
Price to Earnings Ratio26.48-26.48-19.24-14.31-39.69-
Price-to-Total Gains Ratio13.45-13.45-10.49-8.68-81.98-
Price to Book Ratio4.08-4.08-2.96-2.44-2.67-
Price-to-Total Gains Ratio13.45-13.45-10.49-8.68-81.98-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.009705
Number of shares497
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share0.180.11
Usd Total Gains Per Share0.190.11
Gains per Quarter (497 shares)92.8256.28
Gains per Year (497 shares)371.27225.10
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1133583617218215
22771673213437440
3401073110320655665
4541431147427874890
567178918453310921115
681214722164013111340
794250525874715291565
8108286229585317481790
9121322033296019662015
10135357837006621852240

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%2.00.00.0100.0%4.00.00.0100.0%9.00.00.0100.0%11.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%2.00.00.0100.0%4.00.00.0100.0%8.01.00.088.9%10.01.00.090.9%
Dividend per Share1.00.00.0100.0%2.00.00.0100.0%4.00.00.0100.0%9.00.00.0100.0%11.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%2.00.00.0100.0%4.00.00.0100.0%9.00.00.0100.0%11.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Marksans Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--15.92715.9270%--12.532+27%9.725+64%4.996+219%
Book Value Per Share--54.43854.4380%--46.474+17%35.995+51%22.859+138%
Current Ratio--4.6184.6180%--4.765-3%3.982+16%2.912+59%
Debt To Asset Ratio--0.2390.2390%--0.221+8%0.247-3%0.307-22%
Debt To Equity Ratio--0.3130.3130%--0.284+10%0.330-5%0.458-32%
Dividend Per Share--0.6000.6000%--0.412+46%0.296+103%0.318+88%
Enterprise Value--100079339812.500100079339812.5000%--67360711275.000+49%42893945155.500+133%25233122484.667+297%
Eps--8.3988.3980%--7.137+18%6.137+37%3.579+135%
Ev To Sales Ratio--3.8163.8160%--2.843+34%2.066+85%1.618+136%
Free Cash Flow Per Share--0.7450.7450%--2.400-69%2.331-68%1.188-37%
Free Cash Flow To Equity Per Share---0.693-0.6930%--3.864-118%3.456-120%1.244-156%
Gross Profit Margin--1.0001.0000%--1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--23.662----------
Intrinsic Value_10Y_min---27.483----------
Intrinsic Value_1Y_max--2.399----------
Intrinsic Value_1Y_min--0.196----------
Intrinsic Value_3Y_max--7.187----------
Intrinsic Value_3Y_min---1.963----------
Intrinsic Value_5Y_max--11.950----------
Intrinsic Value_5Y_min---6.902----------
Market Cap72796492054.400-38%100760959812.500100760959812.5000%--66352236275.000+52%42948489505.500+135%26535458100.222+280%
Net Profit Margin--0.1450.1450%--0.144+0%0.146-1%0.100+45%
Operating Margin----0%---0%-0%0.057-100%
Operating Ratio--0.4690.4690%--0.483-3%0.479-2%1.038-55%
Pb Ratio3.267-25%4.0844.0840%--2.957+38%2.443+67%2.666+53%
Pe Ratio21.177-25%26.47626.4760%--19.235+38%14.309+85%39.686-33%
Price Per Share177.850-25%222.350222.3500%--146.420+52%97.085+129%61.343+262%
Price To Free Cash Flow Ratio238.836-25%298.595298.5950%--157.988+89%91.664+226%48.573+515%
Price To Total Gains Ratio10.761-25%13.45413.4540%--10.491+28%8.682+55%81.977-84%
Quick Ratio--3.0493.0490%--3.672-17%2.990+2%1.916+59%
Return On Assets--0.1170.1170%--0.120-2%0.136-14%0.104+13%
Return On Equity--0.1540.1540%--0.153+1%0.182-15%0.146+5%
Total Gains Per Share--16.52716.5270%--12.945+28%10.021+65%5.314+211%
Usd Book Value--278761056.000278761056.0000%--237982181.000+17%177998700.507+57%110846962.485+151%
Usd Book Value Change Per Share--0.1800.1800%--0.142+27%0.110+64%0.056+219%
Usd Book Value Per Share--0.6150.6150%--0.525+17%0.407+51%0.258+138%
Usd Dividend Per Share--0.0070.0070%--0.005+46%0.003+103%0.004+88%
Usd Enterprise Value--1130896539.8811130896539.8810%--761176037.408+49%484701580.257+133%285134284.077+297%
Usd Eps--0.0950.0950%--0.081+18%0.069+37%0.040+135%
Usd Free Cash Flow--3813185.0003813185.0000%--12290219.000-69%11378249.082-66%5756861.074-34%
Usd Free Cash Flow Per Share--0.0080.0080%--0.027-69%0.026-68%0.013-37%
Usd Free Cash Flow To Equity Per Share---0.008-0.0080%--0.044-118%0.039-120%0.014-156%
Usd Market Cap822600360.215-38%1138598845.8811138598845.8810%--749780269.908+52%485317931.412+135%299850676.533+280%
Usd Price Per Share2.010-25%2.5132.5130%--1.655+52%1.097+129%0.693+262%
Usd Profit--43004975.00043004975.0000%--36548889.500+18%30153821.175+43%17341251.552+148%
Usd Revenue--296381485.000296381485.0000%--252836596.000+17%207411637.097+43%151287697.001+96%
Usd Total Gains Per Share--0.1870.1870%--0.146+28%0.113+65%0.060+211%
 EOD+4 -4MRQTTM+0 -0YOY+0 -03Y+23 -145Y+25 -1210Y+28 -10

3.3 Fundamental Score

Let's check the fundamental score of Marksans Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.177
Price to Book Ratio (EOD)Between0-13.267
Net Profit Margin (MRQ)Greater than00.145
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.049
Current Ratio (MRQ)Greater than14.618
Debt to Asset Ratio (MRQ)Less than10.239
Debt to Equity Ratio (MRQ)Less than10.313
Return on Equity (MRQ)Greater than0.150.154
Return on Assets (MRQ)Greater than0.050.117
Total7/10 (70.0%)

3.4 Technical Score

Let's check the technical score of Marksans Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose180.850
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, researches, develops, manufactures, markets, distributes, and sells generic pharmaceutical formulations in North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the analgesic, anti-inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, pain management, neurology, antacid, hormonal, antifungal, antiulcerative, cardiovascular and central nervous system, vitamin, cough and cold, dermatology, gastrointestinal, gynecology, cephalosporin, injectable, antibacterial, hypertension, oncology, and antibiotics and anti-allergic therapeutic areas. It also provides contract research and manufacturing services; and develops and out-licenses patented products. The company was incorporated in 1992 and is headquartered in Mumbai, India.

Fundamental data was last updated by Penke on 2025-10-01 02:20:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Marksans Pharma Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compareΒ Marksans Pharma Limited to theΒ Drug Manufacturers - Major industry mean.
  • A Net Profit Margin of 14.5%Β means thatΒ ₹0.15 for each ₹1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Marksans Pharma Limited:

  • The MRQ is 14.5%. The company is making a huge profit. +2
  • The TTM is 14.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.5%TTM14.5%0.0%
TTM14.5%5Y14.6%-0.1%
5Y14.6%10Y10.0%+4.6%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ14.5%10.4%+4.1%
TTM14.5%10.4%+4.1%
3Y14.4%10.5%+3.9%
5Y14.6%11.3%+3.3%
10Y10.0%10.0%0.0%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Marksans Pharma Limited is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Marksans Pharma Limited to theΒ Drug Manufacturers - Major industry mean.
  • 11.7% Return on Assets means thatΒ Marksans Pharma Limited generatedΒ ₹0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Marksans Pharma Limited:

  • The MRQ is 11.7%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 11.7%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ11.7%TTM11.7%0.0%
TTM11.7%5Y13.6%-1.8%
5Y13.6%10Y10.4%+3.2%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ11.7%7.6%+4.1%
TTM11.7%7.6%+4.1%
3Y12.0%9.0%+3.0%
5Y13.6%10.0%+3.6%
10Y10.4%8.8%+1.6%
4.3.1.3. Return on Equity

Shows how efficient Marksans Pharma Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Marksans Pharma Limited to theΒ Drug Manufacturers - Major industry mean.
  • 15.4% Return on Equity means Marksans Pharma Limited generated ₹0.15Β for eachΒ ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Marksans Pharma Limited:

  • The MRQ is 15.4%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.4%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.4%TTM15.4%0.0%
TTM15.4%5Y18.2%-2.7%
5Y18.2%10Y14.6%+3.5%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ15.4%13.5%+1.9%
TTM15.4%13.5%+1.9%
3Y15.3%14.2%+1.1%
5Y18.2%15.0%+3.2%
10Y14.6%14.6%+0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Marksans Pharma Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Marksans Pharma Limited is operatingΒ .

  • Measures how much profit Marksans Pharma Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Marksans Pharma Limited to theΒ Drug Manufacturers - Major industry mean.
  • An Operating Margin of 0.0%Β means the company generated ₹0.00 Β for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Marksans Pharma Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-5Y-0.0%
5Y-10Y5.7%-5.7%
4.3.2.2. Operating Ratio

Measures how efficient Marksans Pharma Limited is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Major industry mean).
  • An Operation Ratio of 0.47 means that the operating costs are ₹0.47 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.469. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.469. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.469TTM0.4690.000
TTM0.4695Y0.479-0.011
5Y0.47910Y1.038-0.558
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4690.4690.000
TTM0.4690.4690.000
3Y0.4830.489-0.006
5Y0.4790.487-0.008
10Y1.0380.951+0.087
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Marksans Pharma Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Marksans Pharma Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Major industry mean).
  • A Current Ratio of 4.62Β means the company has ₹4.62 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Marksans Pharma Limited:

  • The MRQ is 4.618. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.618. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.618TTM4.6180.000
TTM4.6185Y3.982+0.636
5Y3.98210Y2.912+1.070
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6183.398+1.220
TTM4.6183.398+1.220
3Y4.7653.406+1.359
5Y3.9823.071+0.911
10Y2.9122.634+0.278
4.4.3.2. Quick Ratio

Measures if Marksans Pharma Limited is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Marksans Pharma Limited to theΒ Drug Manufacturers - Major industry mean.
  • A Quick Ratio of 3.05Β means the company can pay off ₹3.05 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Marksans Pharma Limited:

  • The MRQ is 3.049. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.049. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.049TTM3.0490.000
TTM3.0495Y2.990+0.059
5Y2.99010Y1.916+1.074
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0493.049+0.000
TTM3.0493.049+0.000
3Y3.6723.631+0.041
5Y2.9902.9900.000
10Y1.9161.9160.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Marksans Pharma Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Marksans Pharma LimitedΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Marksans Pharma Limited to Drug Manufacturers - Major industry mean.
  • A Debt to Asset Ratio of 0.24Β means that Marksans Pharma Limited assets areΒ financed with 23.9% credit (debt) and the remaining percentage (100% - 23.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.239. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.239. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.239TTM0.2390.000
TTM0.2395Y0.247-0.008
5Y0.24710Y0.307-0.061
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2390.2390.000
TTM0.2390.2390.000
3Y0.2210.243-0.022
5Y0.2470.263-0.016
10Y0.3070.307+0.000
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Marksans Pharma Limited is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Marksans Pharma Limited to theΒ Drug Manufacturers - Major industry mean.
  • A Debt to Equity ratio of 31.3% means that company has ₹0.31 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.313. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.313. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.313TTM0.3130.000
TTM0.3135Y0.330-0.016
5Y0.33010Y0.458-0.128
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3130.313+0.000
TTM0.3130.313+0.000
3Y0.2840.321-0.037
5Y0.3300.359-0.029
10Y0.4580.484-0.026
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every ₹1 in earnings Marksans Pharma Limited generates.

  • Above 15 is considered overpriced butΒ always compareΒ Marksans Pharma Limited to theΒ Drug Manufacturers - Major industry mean.
  • A PE ratio of 26.48 means the investor is paying ₹26.48Β for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Marksans Pharma Limited:

  • The EOD is 21.177. Based on the earnings, the company is fair priced.
  • The MRQ is 26.476. Based on the earnings, the company is overpriced. -1
  • The TTM is 26.476. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD21.177MRQ26.476-5.299
MRQ26.476TTM26.4760.000
TTM26.4765Y14.309+12.167
5Y14.30910Y39.686-25.376
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD21.17726.566-5.389
MRQ26.47625.187+1.289
TTM26.47625.187+1.289
3Y19.23519.235+0.000
5Y14.30919.162-4.853
10Y39.68619.339+20.347
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Marksans Pharma Limited:

  • The EOD is 238.836. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 298.595. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 298.595. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD238.836MRQ298.595-59.759
MRQ298.595TTM298.5950.000
TTM298.5955Y91.664+206.932
5Y91.66410Y48.573+43.091
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD238.83647.564+191.272
MRQ298.59540.908+257.687
TTM298.59540.908+257.687
3Y157.98830.603+127.385
5Y91.66423.918+67.746
10Y48.5732.194+46.379
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Marksans Pharma Limited is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Major industry mean).
  • A PB ratio of 4.08 means the investor is paying ₹4.08Β for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Marksans Pharma Limited:

  • The EOD is 3.267. Based on the equity, the company is fair priced.
  • The MRQ is 4.084. Based on the equity, the company is fair priced.
  • The TTM is 4.084. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.267MRQ4.084-0.817
MRQ4.084TTM4.0840.000
TTM4.0845Y2.443+1.642
5Y2.44310Y2.666-0.223
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD3.2673.267+0.000
MRQ4.0843.246+0.838
TTM4.0843.246+0.838
3Y2.9572.606+0.351
5Y2.4432.4430.000
10Y2.6662.043+0.623
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets32,396,320
Total Liabilities7,727,200
Total Stockholder Equity24,669,120
 As reported
Total Liabilities 7,727,200
Total Stockholder Equity+ 24,669,120
Total Assets = 32,396,320

Assets

Total Assets32,396,320
Total Current Assets22,041,210
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 2,785,730
Short-term Investments 2,087,720
Net Receivables 5,421,870
Inventory 8,582,300
Other Current Assets 18,060
Total Current Assets  (as reported)22,041,210
Total Current Assets  (calculated)18,895,680
+/- 3,145,530
Long-term Assets
Property Plant Equipment 8,954,090
Goodwill 409,280
Intangible Assets 727,320
Long-term Assets  (as reported)0
Long-term Assets  (calculated)10,090,690
+/- 10,090,690

Liabilities & Shareholders' Equity

Total Current Liabilities4,773,390
Long-term Liabilities0
Total Stockholder Equity24,669,120
Total Current Liabilities
Short-term Debt 230,850
Total Current Liabilities  (as reported)4,773,390
Total Current Liabilities  (calculated)230,850
+/- 4,542,540
Long-term Liabilities
Long term Debt Total 2,633,290
Capital Lease Obligations Min Short Term Debt-230,850
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)2,402,440
+/- 2,402,440
Total Stockholder Equity
Common Stock453,160
Retained Earnings 17,499,090
Capital Surplus 5,044,980
Other Stockholders Equity 1,671,890
Total Stockholder Equity (as reported)24,669,120
Total Stockholder Equity (calculated)24,669,120
+/-0
Other
Cash And Equivalents2,172,130
Cash and Short Term Investments 7,045,580
Common Stock Shares Outstanding 453,164
Liabilities and Stockholders Equity 32,396,320
Net Working Capital 17,267,820



6.2. Balance Sheets Structured

Currency in INR. All numbers in thousands.

 Trend2025-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
4,900,953
6,755,546
7,199,981
7,518,058
7,321,852
8,037,084
8,968,401
12,282,511
16,401,000
21,903,890
32,396,320
32,396,32021,903,89016,401,00012,282,5118,968,4018,037,0847,321,8527,518,0587,199,9816,755,5464,900,953
   > Total Current Assets 
3,429,451
5,088,315
4,402,419
4,838,826
4,505,367
5,314,419
5,901,874
9,022,513
12,012,000
16,753,010
22,041,210
22,041,21016,753,01012,012,0009,022,5135,901,8745,314,4194,505,3674,838,8264,402,4195,088,3153,429,451
       Cash And Cash Equivalents 
469,470
1,852,652
353,013
250,494
397,166
328,550
937,271
515,988
1,566,860
875,230
2,785,730
2,785,730875,2301,566,860515,988937,271328,550397,166250,494353,0131,852,652469,470
       Short-term Investments 
0
0
0
0
0
0
0
1,577,816
1,402,870
3,326,470
2,087,720
2,087,7203,326,4701,402,8701,577,8160000000
       Net Receivables 
1,696,072
1,834,544
2,172,930
2,475,811
1,769,056
1,765,969
2,433,517
2,713,813
3,947,780
4,168,460
5,421,870
5,421,8704,168,4603,947,7802,713,8132,433,5171,765,9691,769,0562,475,8112,172,9301,834,5441,696,072
       Inventory 
1,025,887
1,301,068
1,677,917
1,900,870
2,181,241
2,932,461
2,418,439
4,043,197
4,244,420
4,847,390
8,582,300
8,582,3004,847,3904,244,4204,043,1972,418,4392,932,4612,181,2411,900,8701,677,9171,301,0681,025,887
       Other Current Assets 
238,021
100,051
3,772
2,024
100,980
217,212
110,601
171,700
322,320
361,910
18,060
18,060361,910322,320171,700110,601217,212100,9802,0243,772100,051238,021
   > Long-term Assets 
0
0
0
2,684,683
2,801,941
2,722,664
3,066,528
0
0
0
0
00003,066,5282,722,6642,801,9412,684,683000
       Property Plant Equipment 
724,825
1,023,705
1,641,388
1,648,624
1,863,685
1,980,821
2,200,764
2,540,209
3,422,870
3,868,890
8,954,090
8,954,0903,868,8903,422,8702,540,2092,200,7641,980,8211,863,6851,648,6241,641,3881,023,705724,825
       Goodwill 
311,178
282,927
779,015
696,829
617,487
314,499
243,758
195,862
300,250
384,890
409,280
409,280384,890300,250195,862243,758314,499617,487696,829779,015282,927311,178
       Intangible Assets 
420,493
352,344
276,142
327,898
312,603
401,943
826,398
474,357
585,690
707,970
727,320
727,320707,970585,690474,357826,398401,943312,603327,898276,142352,344420,493
> Total Liabilities 
3,412,773
2,876,906
2,751,115
3,183,734
2,613,206
2,612,260
2,608,259
3,417,561
4,378,300
4,452,270
7,727,200
7,727,2004,452,2704,378,3003,417,5612,608,2592,612,2602,613,2063,183,7342,751,1152,876,9063,412,773
   > Total Current Liabilities 
3,191,194
2,862,355
2,511,203
2,960,583
2,346,796
2,326,242
2,196,858
2,983,994
3,562,180
3,409,900
4,773,390
4,773,3903,409,9003,562,1802,983,9942,196,8582,326,2422,346,7962,960,5832,511,2032,862,3553,191,194
       Short-term Debt 
2,219,326
1,220,113
878,929
1,097,103
1,174,132
999,087
188,425
187,400
412,920
415,880
230,850
230,850415,880412,920187,400188,425999,0871,174,1321,097,103878,9291,220,1132,219,326
       Short Long Term Debt 
2,219,326
1,220,113
884,812
1,097,103
1,179,621
1,002,165
188,884
0
0
0
0
0000188,8841,002,1651,179,6211,097,103884,8121,220,1132,219,326
       Accounts payable 
831,818
1,070,195
1,189,802
1,617,841
674,806
1,060,692
1,045,010
0
0
0
0
00001,045,0101,060,692674,8061,617,8411,189,8021,070,195831,818
       Other Current Liabilities 
301,293
523,437
464,946
5,993
5,828
132,602
885,076
0
0
0
0
0000885,076132,6025,8285,993464,946523,437301,293
   > Long-term Liabilities 
0
0
0
0
156,371
183,850
280,300
0
0
0
0
0000280,300183,850156,3710000
       Long term Debt Total 
0
0
125,000
110,000
100,000
100,000
50,000
143,257
414,340
656,890
2,633,290
2,633,290656,890414,340143,25750,000100,000100,000110,000125,00000
       Capital Lease Obligations 
0
0
0
0
0
0
107,615
0
0
0
0
0000107,615000000
> Total Stockholder Equity
1,286,824
3,672,639
4,448,865
4,334,325
4,708,646
5,424,823
6,360,143
8,864,950
12,022,700
17,451,620
24,669,120
24,669,12017,451,62012,022,7008,864,9506,360,1435,424,8234,708,6464,334,3254,448,8653,672,6391,286,824
   Common Stock
385,307
409,314
409,314
409,314
409,314
409,314
409,314
409,314
409,310
453,160
453,160
453,160453,160409,310409,314409,314409,314409,314409,314409,314409,314385,307
   Retained Earnings 
518,755
1,611,772
2,258,024
2,175,794
2,481,786
3,202,272
5,950,829
6,571,749
9,246,580
11,054,990
17,499,090
17,499,09011,054,9909,246,5806,571,7495,950,8293,202,2722,481,7862,175,7942,258,0241,611,772518,755
   Accumulated Other Comprehensive Income 00000000000
   Capital Surplus 
0
0
1,751,317
1,751,317
1,751,317
1,751,317
1,751,317
1,751,317
1,731,870
5,044,980
5,044,980
5,044,9805,044,9801,731,8701,751,3171,751,3171,751,3171,751,3171,751,3171,751,31700
   Treasury Stock00000000000



6.3. Balance Sheets

Currency in INR. All numbers in thousands.




6.4. Cash Flows

Currency in INR. All numbers in thousands.




6.5. Income Statements

Currency in INR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2025-03-31. Currency in INR. All numbers in thousands.

Gross Profit (+$)
totalRevenue26,228,450
Cost of Revenue-12,294,560
Gross Profit13,933,89013,933,890
 
Operating Income (+$)
Gross Profit13,933,890
Operating Expense-0
Operating Income4,661,11013,933,890
 
Operating Expense (+$)
Research Development0
Selling General Administrative8,301,070
Selling And Marketing Expenses0
Operating Expense08,301,070
 
Net Interest Income (+$)
Interest Income378,890
Interest Expense-0
Other Finance Cost-378,890
Net Interest Income0
 
Pretax Income (+$)
Operating Income4,661,110
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)5,039,6704,661,110
EBIT - interestExpense = 0
3,805,750
3,805,750
Interest Expense0
Earnings Before Interest and Taxes (EBIT)05,039,670
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax5,039,670
Tax Provision-1,213,480
Net Income From Continuing Ops03,826,190
Net Income3,805,750
Net Income Applicable To Common Shares3,805,750
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net00
 

Technical Analysis of Marksans Pharma Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Marksans Pharma Limited. The general trend of Marksans Pharma Limited is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Marksans Pharma Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Marksans Pharma Limited Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Marksans Pharma Limited.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 224.81 < 240.05 < 248.62.

The bearish price targets are: 181.00 > 162.45 > 157.97.

Know someone who trades $524404? Share this with them.πŸ‘‡

Marksans Pharma Limited Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Marksans Pharma Limited. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Marksans Pharma Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Moving Average Convergence/Divergence (MACD) ChartMarksans Pharma Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Marksans Pharma Limited. The current adx is .

Marksans Pharma Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Marksans Pharma Limited.

Marksans Pharma Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Relative Strength Index (RSI) ChartMarksans Pharma Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Marksans Pharma Limited.

Marksans Pharma Limited Daily Stochastic Oscillator ChartMarksans Pharma Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Commodity Channel Index (CCI) ChartMarksans Pharma Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Chande Momentum Oscillator (CMO) ChartMarksans Pharma Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Marksans Pharma Limited.

Marksans Pharma Limited Daily Williams %R ChartMarksans Pharma Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Marksans Pharma Limited.

Marksans Pharma Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Average True Range (ATR) ChartMarksans Pharma Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Marksans Pharma Limited.

Marksans Pharma Limited Daily On-Balance Volume (OBV) ChartMarksans Pharma Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Marksans Pharma Limited.

Marksans Pharma Limited Daily Money Flow Index (MFI) ChartMarksans Pharma Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Marksans Pharma Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-09-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-09-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-10-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-10-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Marksans Pharma Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Marksans Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose180.850
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Marksans Pharma Limited with someone you think should read this too:
  • Are you bullish or bearish on Marksans Pharma Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Marksans Pharma Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Marksans Pharma Limited

I send you an email if I find something interesting about Marksans Pharma Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Marksans Pharma Limited.

Receive notifications about Marksans Pharma Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.